Altimmune Reports 24-Week (12-Week Extension) Trial Results of Pemvidutide for the Treatment of Non-Alcoholic Fatty Liver Disease
Shots:
- The 24wk. (12wk. extension) trial evaluating pemvidutide in 64 patients with NAFLD
- The trial met its 1EPs & 2EPs i.e., patients treated with pemvidutide (1.8 & 2.4mg) achieved mean relative reductions of liver fat content (75.2% & 76.4%); 30% & 50% achieved a reduction in liver fat (92.3% & 100%) & (84.6% & 72.7%), respectively, normalization of liver fat (53.8% & 45.5%), declines in mean serum ALT levels in all patients & with baseline serum ALT ≥30 IU/L
- 80ms reduction in cT1 (75.0% & 100%), mean weight losses of 7.2% while 6.2% at 1.8mg dose, was well tolerated with no ALT elevations, glycemic control was maintained leading improvements in fasting glucose & HbA1c over 24wks., reductions in systolic BP & increases in heart rate, typical of the incretin class of agents
Ref: Altimmune | Image: Altimmune
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
